Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
RESEARCH TOOLSreports
Holding CGTX?
Track your performance easily
Earnings Data
Report Date
Mar 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.19Last Year’s EPS
-$0.27Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 13, 2024
|% Change Since: 5.35%
|Next Earnings Date:Mar 26, 2025
Earnings Call Sentiment|Positive
The earnings call presents a cautiously optimistic outlook for Cognition Therapeutics. The SHINE trial results, while not statistically significant, show promising trends in slowing cognitive decline, which are encouraging for future studies. The company continues to maintain a strong safety profile and financial stability. However, increased expenses and a higher net loss pose challenges. The sentiment overall leans slightly positive given the promising trial results and financial runway.Company Guidance
During the Cognition Therapeutics second quarter 2024 earnings call, the company provided detailed guidance on its clinical and financial progress. The SHINE trial, a Phase II study for CT1812 in mild to moderate Alzheimer's disease, showed a 39% slowing of cognitive decline over six months, evaluated through metrics such as ADAS-Cog 11 and MMSE scales, despite not achieving statistical significance. The trial enrolled 153 participants and assessed multiple cognitive endpoints and safety, with CT1812 demonstrating a favorable safety profile, especially at the 100 mg dose. Financially, the company reported R&D expenses of $11.6 million and a net loss of $7 million for Q2 2024, with cash and cash equivalents of $28.5 million, sufficient to fund operations into the second quarter of 2025. Future plans include longer and larger trials, leveraging grant funding from the NIA, and exploring new dosing strategies in ongoing studies like START and MAGNIFY.Positive Results from SHINE Trial
The SHINE trial showed a 39% slowing of cognitive decline in Alzheimer's patients treated with CT1812 over 6 months, compared to placebo. This is a significant finding compared to recently approved monoclonal antibodies, which showed a 25% to 30% slowing over 18 months.
Strong Safety Profile
CT1812 demonstrated a favorable safety and tolerability profile with most adverse events being mild or moderate. There were no cases of ARIA-E and only one case of asymptomatic ARIA-H.
Encouraging Biomarker Data
The SHINE trial showed significant change in neurofilament light (NfL), a marker of neurodegenerative disease, particularly at the 300-mg dose, supporting CT1812's potential as a synaptoprotective agent.
Financial Stability
As of June 30, 2024, the company had $28.5 million in cash and cash equivalents, with total grant funds remaining from the NIA at $57.3 million, sufficient to fund operations into Q2 2025.
Upcoming SHIMMER Trial Results
The SHIMMER trial, a Phase II study of CT1812 in patients with dementia with Lewy bodies, has completed enrollment and top-line results are expected by year-end.
---
CGTX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CGTX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 13, 2024 | $0.60 | $0.54 | -10.00% |
| Aug 08, 2024 | $0.58 | $0.58 | 0.00% |
| May 07, 2024 | $1.99 | $1.92 | -3.52% |
| Mar 26, 2024 | $1.82 | $1.83 | +0.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cognition Therapeutics (CGTX) report earnings?
Cognition Therapeutics (CGTX) is schdueled to report earning on Mar 26, 2025, TBA Not Confirmed.
What is Cognition Therapeutics (CGTX) earnings time?
Cognition Therapeutics (CGTX) earnings time is at Mar 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CGTX EPS forecast?
CGTX EPS forecast for the fiscal quarter 2024 (Q4) is -$0.19.
---